Ocriplasmin is a medication that is used to treat symptomatic vitreomacular adhesion (VMA) in adults. VMA occurs when the vitreous gel in the eye pulls away from the macula, causing distortion or loss of vision. Ocriplasmin works by breaking down the proteins that are responsible for the adhesion between the vitreous gel and the macula, allowing the gel to separate and relieve the symptoms associated with VMA.

It is important to note that Ocriplasmin is administered as an injection directly into the eye by a healthcare professional. This procedure is typically done in a clinical setting and may require multiple injections depending on the severity of the VMA.

As with any medication, there are potential side effects associated with Ocriplasmin. These can include eye pain, floaters, blurred vision, and increased intraocular pressure. It is important to discuss any concerns or potential side effects with your healthcare provider before starting treatment with Ocriplasmin.

Overall, Ocriplasmin has been shown to be an effective treatment for symptomatic VMA in adults. It is important to follow your healthcare provider’s instructions for administration and monitoring while taking this medication. If you have any questions or concerns about Ocriplasmin or its use, do not hesitate to reach out to your healthcare provider for more information.